A set of 53 individuals from a population highly exposed to airbome hexachlorobenzene (HCB) were selected to study the elimination kinetics ofthis chemical in humans. The volunteers provided blood, 24-hr urine, and feces samples for analysis of HCB and metabolites. The serum HCB concentrations ranged from 2.4 to 1,485 ng/mL (mean * SD, 124 * 278), confirming that this human population has the highest HCB blood levels ever reported. Al analyzed feces samples contained unchanged HCB (range, 11-3,025 ng/g dry weight; mean * SD, 395 * 629). The HCB concentration in feces strongly correlated with HCB in serum (r = 0.85; p < 0.001), suggesting an equilibrium in feces/serum that is compatible with a main pulmonary entrance of the chemical and low intestinal excretion of nonabsorbed foodborne HCB. The equilibrium is also compatible with a nonbiliary passive tasfer of the chemical to the intestinal lumen. Two HCB main metabolites, pentachlorophenol (PCP) and penhlorobenznethiol (PCBT), were detected in 51% and 54% of feces samples, respectively. All urine samples contained PCP and PCBT, confirming the condusions of a previous study [Environ Health Perspect 105:78-83 (1997)]. The comparison between feces and urie showed that whereas daily urinary elimination ofmetabolites may account for 3% of total HCB in blood, intestinal excretion of unchanged HCB may account for about 6%, thus showing the importnce of metabolism in the overall elimfination of HCB.
The elimination of HCB and metabolites by both routes, however, appears to be very small (< 0.05%/day) as compared to the estimated HCB adipose depots. Features of HCB kinetics that we present in this study, i.e., nonsatted intestinal elimination of HCB and excretion in feces and urne of inert glutathione derivatives, may explain, in part, the absence of porphyria cutaea in this human population heavily exposed to HCB. KICy .bttpa/erbpnetl.nie,hs.nih.ov/wdocs/20000/108p595-598to-5fl au/absatc.hbtml Hexachlorobenzene (HCB) is a chlorinated hydrocarbon with a high lipophilicity and a strong tendency to accumulate in food chains and lipid-rich tissues of animals and humans. It is ubiquitous in soil, water, air, and biological matrices. HCB was used as a fungicide for seed treatment, but most countries banned its use during the 1970s; currently, most HCB enters the environment by way of by-products and emissions from the chlorinated solvent industry. It was learned that HCB induces porphyria in humans during an outbreak of porphyria cutanea tarda (PCT) in Turkey in the late 1950s, when several rural populations consumed HCB-contaminated bread (1) . The effects of this chemical were most severe in breast-fed infants. Several decades of research have shown that HCB, in addition to inducing porphyria, has a broad range of toxic effects in experimental animals, including immunotoxicity, endocrine effects, and cancer (1) . However (3) (4) (5) .The authors, however, did not find an association between HCB serum concentrations and the appearance of PCT.
The Flix project was also intended to study HCB disposition in humans. The existence of a cohort of individuals with the highest HCB serum concentrations ever reported provided a unique opportunity to study HCB metabolism and elimination in humans. In a previous report (6) addressing the urinary elimination of HCB metabolites, we found a very strong correlation between HCB serum concentrations and pentachlorobenzenetiol (PCBT) in urine. PCBT is a metabolite that arises from the conjugation of HCB with glutathione and the formation of an N-acetyl-Lcysteine derivative (6) . This metabolite was found to be more concentrated in the urine than pentachlorophenol (PCP), a metabolite that arises from P450-mediated hydroxilation; this suggests the existence of an important detoxication pathway that leads to the formation ofa mercapturic acid derivative.
A more comprehensive approach to HCB elimination kinetics in humans, however, required the quantification of HCB and its metabolites in feces and the comparison between both major elimination pathways. In this report we present this quantification based on a new subset of individuals from the Flix project who provided serum, urine, and feces samples for study.
Materials and Methods
Study population. An epidemiologic crosssectional study was HCB and metabolites were extracted twice with 5 mL benzene; the solvent extracts were concentrated to 0.5 mL and treated with 0.5 mL diazoethane in diethyl ether.
After derivatization (30 min in the dark), the excess diazoethane was removed under an N2 stream, the solvent extracts were concentrated to approximately 0.1 mL, and n-hexane (2 mL) was added. The resulting mixture was cleaned with H2S04, and the organic phase was separated and concentrated to 25 pL. HCB and ethyl derivatives of PCP and PCBT were analyzed by gas chromatography (GC; Hewlett Packard 5890 II, Hewlett Packard, Palo Alto, CA) with 63Ni electron capture detection (ECD). Recovery of HCB, PCP, and PCBT was assayed with spiked wet feces and ranged between 88 and 109%. The limit of detection for HCB, PCP, and PCBT was 5 ng/g of dry feces. Metabolites of HCB in urine were analyzed as previously described (6) . Briefly, aliquots of 24-hr urine were spiked with aldrin as an internal standard, hydrolyzed with NaOH, extracted with toluene, and derivatized with diazoethane. The main urinary HCB metabolites (conjugated PCP and pentachlorophenyl N-acetyl cysteine) were analyzed by GC-ECD as ethyl derivatives of free PCP and PCBT and confirmed by selective ion monitoring mass spectrometry (SIM-MS). Quantitation was calculated as micrograms of metabolites excreted in 24 hr. The detection limit was 0.5 pg/24 hr. The HCB in sera was analyzed as previously described (6) . Briefly, serum aliquots were spiked with tetrabromobenzene as an internal standard and treated with n-hexane and sulfuric acid. HCB Table 1 , and the frequency distribution is shown in Figure 1 .
The HCB concentration in feces was strongly associated with HCB in serum (r = 0.85; p < 0.0001; Figure 2 , Table 2 ), suggesting that only a small amount of the chemical found in feces is nonabsorbed intestinal HCB. Among the remaining variables, only sex was associated with HCB concentrations in feces (Table 2) . Because men had significantly higher blood HCB concentrations than women, this association between sex and HCB in feces disappeared after adjusting for blood HCB concentrations in a multiple regression analysis. The association between HCB in blood and feces was stronger in males (slope = 0.89; SE = 0.05) than in females (0.32; SE = 0.29), and this difference was statistically significant (p = 0.046). The association between HCB concentrations in blood and those in feces was not confounded by the variables included in Table 2 . Also, there were no differences in the association of HCB concentrations in blood and feces by age or body mass index. PCP was detectable in only 51% of the feces samples (range 5-70 ng/g; Table 1 ) and PCBT was detectable in 54% (range 5-139 ng/g). We were unable to detect other known metabolites of HCB in rodents, such as tetrachlorohydroquinone and tetrachloro-1,4-benzenedithiol.
As expected from the lipophilicity of the compound, HCB could not be detected in any of the urine samples (detection limit 0.5 ng/mL), whereas PCP and PCBT were detected in 100% (Table 1) . PCBT in urine strongly correlated with HCB in serum (r = 0.80), thus confirming the findings of the previous study using a different subset of individuals (6) .
The concentration of HCB in feces does not allow a precise calculation of the amount of HCB that is eliminated daily by the intestines. This would require a (difficult) collection of 24-hr feces from all of the participants. Thus, an accurate comparison between the amount of HCB eliminated through feces and urine is not possible. Based on the data in Table 1 , however, we estimated the excretion of HCB in feces; these estimations are presented in Table 3 Table 3 ). Approximately 0.9 pg 24-hr metabolites (sum of the GM of the PCP concentration in feces x 70 g/24 hr dry feces = 0.42 pg plus the GM of the PCBT concentration x 70 g = 0.53 pg; Table 1 ) could also be excreted in feces (still only detected in 50% of the samples).
Discussion
This is the first study of humans in which the HCB elimination pattern can be studied in a general population highly exposed to HCB and with the highest HCB serum concentrations ever reported (5). The quantitative results shown in Table 1 clearly suggest that in humans there is a major elimination of unmetabolized HCB in feces. These findings agree with studies performed in rhesus monkeys fed [14C]HCB, which found that a significant amount of the radioactivity detected in feces corresponded to the unchanged parent compound (8) . In mammals, the (9) . In some cases, virtually unmetabolizable PCB congeners (2,4,5,2',4',5'-hexachlorobiphenyl) are eliminated only in feces (10) .
According to our results for HCB, there is not such a clear shift in humans. We found a large amount of unchanged HCB excreted in feces, but the polar derivatives PCP and PCBT still make up a relatively high proportion of the total output.
HCB found in feces may be, in part, the nonabsorbed and recently ingested compound. However, the strong correlation between HCB content in feces and sera ( Figure 2 ) suggests an equilibrium kinetics with very few variations because of nonabsorbed foodborne HCB. Previous reports have shown that the population under study is exposed to HCB primarily through inhalation of contaminated air (2); the appearance of a correlation between feces and blood is compatible with a main pulmonary entrance and incompatible with irregular amounts of HCB that were recently ingested, not absorbed, and currently circulate in the gastrointestinal tract.
Some authors have suggested that fecal elimination of some lipophylic chemicals is produced mainly by direct passive transfer to the intestinal lumen and not by biliary secretion (11) . This could be the case for HCB in humans because mineral oil has been shown to stimulate the intestinal excretion of HCB in rhesus monkeys (12) . Our results do not directly confirm this possibility, but the relatively high concentrations of unchanged HCB found in feces and the strong correlation of serum and feces (which in turn suggests a correlation between adipose tissue, serum, and feces) seem compatible with the hypothesis of a nonbiliary passive transfer that is probably mediated by the lymphatics independent of the liver.
The higher concentration of HCB in feces from men as compared to women is dependent on the higher serum HCB found in men in this population subset. A similar difference has also been found in the overall serum study (5) . The most probable explanation for these sex differences is that more men that women were employed in an electrochemical factory, which was the main determinant of the variation in HCB body burden (5 Table  3 ). These tentative calculations show that the total daily elimination of HCB and metabolites by both routes (urine and feces) may be very small as compared to the adipose depots (0.029%/day; relative to previously estimated GM 55.5 mg of HCB adipose burden) and even as compared to the total HCB in blood (10%/day, relative to GM 163 pg; Table 3 ). Assuming a first order kinetics, this excretion rate would suppose an average estimated whole-body HCB half-life of 6 years, which is in accordance with the upper limit of calculations made in monkeys (16) .
Previous studies have addressed the health status of this HCB-exposed human population (2, 3) . An increase in soft-tissue sarcoma and thyroid cancer in men was observed, but prevalence of self-reported common chronic diseases, thyroid pathology, Parkinson's disease, all cancers, and reproductive outcomes did not differ from other populations. Most striking was the absence of porphyria cutanea, a disease known to be associated with HCB exposure in humans (4). However, several peculiarities of HCB kinetics that emerge from this study (adipose sequestration, nonsaturated elimination of unchanged compound by feces, nonsaturated formation of inert glutathione derivatives) could explain why HCB, even present in this human population with the highest blood concentrations ever reported, may not be high enough to trigger hepatic toxicity or other effects typically associated with organochlorines.
